Open Access

Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer

  • Authors:
    • Tomohiro Kunishige
    • Kazuhiro Migita
    • Sohei Matsumoto
    • Kohei Wakatsuki
    • Hiroshi Nakade
    • Shintaro Miyao
    • Hiroki Kuniyasu
    • Masayuki Sho
  • View Affiliations

  • Published online on: July 9, 2020     https://doi.org/10.3892/ol.2020.11840
  • Pages: 2919-2927
  • Copyright: © Kunishige et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Ring box protein‑1 (RBX1) is an essential component of the S‑phase kinase‑associated protein, Cullin and F‑box containing ubiquitin ligases. Overexpression of RBX1 has been reported in several cancer types; however, little is known regarding the prognostic value and role of RBX1 in esophageal cancer. The present study examined 120 patients with esophageal cancer (EC) who underwent curative esophagectomy and 61 patients with EC who underwent neoadjuvant combination chemotherapy with docetaxel, cisplatin and 5‑fluorouracil (5‑FU; DCF) using immunohistochemistry. All specimens were classified into two groups according to the percentage of RBX1‑positive tumor cells. In addition, the impact of RBX1 expression on cancer cell proliferation was analyzed in vitro using a small interfering RNA silencing technique. RBX1 expression levels showed significant differences according to tumor size (P<0.001), tumor depth (P=0.002), lymph node metastasis (P=0.004), pathological stage (P=0.001), lymphatic invasion (P=0.001) and venous invasion (P=0.001). The overall survival (OS) rate in the RBX1 high expression group was significantly lower compared with that in the low group (P=0.004). Multivariate analysis demonstrated that RBX1 status was an independent prognostic factor. RBX1 gene silencing inhibited the proliferation of human EC cells and enhanced the antitumor effect of 5‑FU. Among patients who underwent neoadjuvant DCF therapy, the RBX1 high expression group had a significantly lower OS rate compared with that of the RBX1‑low group (P<0.001). In conclusion, RBX1 has notable prognostic value, and RBX1 may serve an important function in the tumor progression of EC.

Related Articles

Journal Cover

September-2020
Volume 20 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kunishige T, Migita K, Matsumoto S, Wakatsuki K, Nakade H, Miyao S, Kuniyasu H and Sho M: Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer. Oncol Lett 20: 2919-2927, 2020
APA
Kunishige, T., Migita, K., Matsumoto, S., Wakatsuki, K., Nakade, H., Miyao, S. ... Sho, M. (2020). Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer. Oncology Letters, 20, 2919-2927. https://doi.org/10.3892/ol.2020.11840
MLA
Kunishige, T., Migita, K., Matsumoto, S., Wakatsuki, K., Nakade, H., Miyao, S., Kuniyasu, H., Sho, M."Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer". Oncology Letters 20.3 (2020): 2919-2927.
Chicago
Kunishige, T., Migita, K., Matsumoto, S., Wakatsuki, K., Nakade, H., Miyao, S., Kuniyasu, H., Sho, M."Ring box protein-1 is associated with a poor prognosis and tumor progression in esophageal cancer". Oncology Letters 20, no. 3 (2020): 2919-2927. https://doi.org/10.3892/ol.2020.11840